L&S Knock-Out MRK 12.06.2024/ DE000LX3HG89 /
2024-05-09 9:40:06 PM | Chg.+0.02 | Bid9:40:06 PM | Ask9:40:06 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.26EUR | +8.33% | 0.26 Bid Size: - |
0.27 Ask Size: - |
MERCK KGAA O.N. | 130.00 EUR | 2024-06-12 | Call |
GlobeNewswire
2:00 PM
PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights
GlobeNewswire
12:59 PM
Mersana Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results
GlobeNewswire
05-08
CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
05-07
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination wi...
GlobeNewswire
05-06
Press Release Biocartis NV: Biocartis and Merck to Collaborate on Improving Patient Access to Person...
GlobeNewswire
03-04
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Ger...
GlobeNewswire
2023-12-21
Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac ...
GlobeNewswire
2023-12-14
ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development an...
GlobeNewswire
2023-10-17
ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, NJ, USA